



Original/Alimentos funcionales

# A coconut extra virgin oil-rich diet increases HDL cholesterol and decreases waist circumference and body mass in coronary artery disease patients

Diuli A. Cardoso<sup>1</sup>, Annie S. B. Moreira<sup>2</sup>, Glaucia M. M. de Oliveira<sup>1</sup>, Ronir Raggio Luiz<sup>3</sup> and Glorimar Rosa<sup>4</sup>

<sup>1</sup>Postgraduate Program in Cardiology at the School of Medicine, Universidade Federal do Rio de Janeiro (UFRJ). <sup>2</sup>Applied Nutrition Department of Universidade do Estado do Rio de Janeiro (UERJ); Research dietitian and professor at Instituto Nacional de Cardiologia (INC). <sup>3</sup>Institute for Collective Health Studies, Federal University of Rio de Janeiro, Rio de Janeiro. <sup>4</sup>Department of Nutrition and Dietetics, Josué de Castro Nutrition Institute of Universidade Federal do Rio de Janeiro (UFRJ), Brazil.

Abstract

**Introduction:** saturated fat restriction has been recommended for coronary arterial disease, but the role of coconut oil (*Cocos nucifera L.*) extra virgin, lauric acid source in the management of lipid profile remains unclear.

**Objective:** to evaluate the effect of nutritional treatment associated with the consumption of extra virgin coconut oil in anthropometric parameters and lipid profile.

**Methods:** we conducted a longitudinal study of 116 adults of both sexes presenting CAD. Patients were followed in two stages: the first stage (basal-3 months), intensive nutritional treatment. In the second stage (3-6 months), the subjects were divided into two groups: diet group associated with extra virgin coconut oil consumption (GDOC) and diet group (DG). Held monthly anthropometric measurements: body mass, waist circumference (WC), neck circumference (PP), body mass index (BMI). Gauged to collected blood pressure and blood samples were fasted for 12 hours, for total cholesterol analysis and fractions apoproteins (Apo A-1 and B), glucose, glycated hemoglobin (HbA1C), insulin (I). Comparing the averages at the beginning and end of the study employing the paired Student t-independent. And set the diastolic blood pressure by BMI using ANOVA. Analyses were performed using the SPSS statistical package, being significant  $p < 0.05$ .

**Results:** the mean age of the population was  $62.4 \pm 7.7$  years, 63.2% male, 70% elderly, 77.6% infarcted, 52.6% with angina, hypertension and dyslipidemia 100%. In the first stage the nutritional treatment reduced body weight, WC, BMI and PP and insulin concentrations, HbA1C, HOMA-IR and QUICK, without changing the other parameters. In the second stage of the study, it was observed that the GDOC maintained the reduction of body mass, BMI, WC, with a significant difference between groups for DC ( $-2.1 \pm 2,7\text{cm}$ ;  $p < 0.01$ ).

EL ACEITE DE COCO VIRGEN EXTRA RICO EN ÁCIDOS GRASOS INCREMENTA EL COLESTEROL HDL Y DISMINUYE LA CIRCUNFERENCIA DE LA CINTURA Y LA MASA CORPORAL EN PACIENTES CON ENFERMEDADES DE LA ARTERIA CORONARIA

Resumen

**Introducción:** el aceite de coco (*Cocos nucifera L.*) virgen extra contiene una alta proporción de ácidos grasos de cadena media que parecen contribuir a la reducción del peso y podría ayudar en la prevención secundaria de la enfermedad arterial coronaria (EAC).

**Objetivo:** evaluar el efecto del tratamiento nutricional asociado con el consumo de aceite de coco virgen extra en los parámetros antropométricos y el perfil lipídico.

**Métodos:** se realizó un estudio longitudinal de 116 adultos de ambos sexos que presentan CAD. Los pacientes fueron seguidos en dos etapas: en la primera etapa (basal-3 meses), se llevó a cabo un tratamiento nutricional intensivo. En la segunda etapa (3-6 días), los sujetos fueron divididos en dos grupos: grupo asociado con el consumo de aceite extra virgen de coco (GDOC) y el grupo de dieta (GD). Se realizaron mediciones mensuales antropométricas: peso, circunferencia de la cintura (CC), circunferencia del cuello (PP) e índice de masa corporal (IMC). Se tomó la presión arterial y muestras de sangre recogidas en ayunas durante 12 horas para el análisis de colesterol total y lipoproteínas, apoproteínas (Apo A-1 y B), glucosa, hemoglobina glucosilada (HbA1c) e insulina (I). Se compararon los promedios al principio y al final del estudio mediante el test t de Student-independiente. Se ajustó la presión arterial diastólica por el IMC mediante ANOVA. Los análisis se realizaron con el paquete estadístico SPSS, siendo significativa  $p < 0.05$ .

**Resultados:** la edad media de la población fue de  $62,4 \pm 7,7$  años, el 63,2% hombres, 70% mayores, el 77,6% con infarto de miocardio, el 52,6% con angina de pecho y el 100% con hipertensión arterial y dislipidemia. En la primera etapa del tratamiento nutricional se redujeron las concentraciones de insulina, peso, WC, IMC y PP, HbA1C, HOMA-IR y rápido, sin cambiar otros parámetros. En la segunda etapa del estudio se observó que la GDOC mantiene la reducción del peso, BMI, WC, con una diferencia significativa entre los grupos para DC ( $-2,1 \pm 2,7 \text{ cm}$ ;  $p < 0,01$ ).

Correspondence: Annie Bello Moreira.  
Universidade do Estado do Rio de Janeiro.  
Rua São Francisco Xavier, 524, Pavilhão João Lyra Filho,  
12.º andar, Bloco D, Cep: 20559-900 Rio de Janeiro, RJ – Brasil.  
E-mail: anniebello@gmail.com

Recibido: 14-VII-2015.  
Aceptado: 17-VIII-2015.

In addition, there was an increase in HDL-C concentrations, Apo A, with significant difference in GD, only for HDL-C ( $3.1 \pm 7.4$  mg/dL;  $p = 0.02$ ).

**Conclusion:** it was observed that the nutritional treatment associated with extra virgin coconut oil consumption reduced the CC and increased HDL-C levels in patients with CAD.

(*Nutr Hosp.* 2015;32:2144-2152)

DOI:10.3305/nh.2015.32.5.9642

Key words: *Coronary artery disease. Nutritional treatment. Secondary prevention and extra virgin coconut oil.*

## Introduction

Secondary prevention for patients with coronary artery disease (CAD) aims to avoid new cardiovascular events<sup>1</sup>. The change towards a healthier lifestyle presents a 44% decrease in mortality from CAD<sup>2,3</sup>. Recent guidelines emphasize the necessity of reducing visceral fat, and controlling blood pressure and dyslipidemia<sup>1,2</sup>.

The adoption of a dietary pattern based on good sources of mono- and polyunsaturated fat, fiber, fruit, vegetables, whole grains, olive oil and nuts results in the decrease of risk factors for cardiovascular disease. On the other hand, according to the National Health and Nutrition Examination Survey (2007-2011), conducted on 759 individuals with CAD, data showed very low compliance to the nutritional and clinical treatment, with only 20% displaying adequate body weight, and 59% having lipid profile control<sup>4</sup>.

New therapeutic targets are necessary to increase compliance to dietary treatments. Due to this necessity, the effects of functional foods<sup>5</sup> have been studied. Although no consensus exists over the subject, functional foods appear to exert some beneficial action on lipid profile and promote better compliance to dietary treatment<sup>6</sup>.

In this context, extra virgin coconut oil (*Cocos nucifera* L.), extracted from the fresh coconut pulp, has been acknowledged for its high proportion of medium-chain fatty acids (MCFA), lauric acid<sup>7</sup> (source of vitamin E), and polyphenols with antioxidant activity<sup>8</sup>. The scientific literature has shown benefits of extra virgin coconut oil to the reduction of body fat<sup>9,10,11</sup>, but there is still controversy over its effects on lipid profile, since it is a source of saturated fat<sup>11 e 12</sup>.

Thus, the aim of this study was to evaluate the effect of a diet rich in coconut oil concerning the improvement of lipid profile and anthropometric measurements.

## Methods

### *Study subjects and design*

We conducted a nonrandomized 6-month clinical trial, with 360 patients being initially screened. The

Además, se produjo un aumento en las concentraciones de HDL-C, Apo A, con una diferencia significativa en GD, solo para HDL-C ( $3,1 \pm 7,4$  mg/dl;  $p = 0,02$ ).

**Conclusión:** se observó que el tratamiento nutricional asociado con el consumo de aceite de coco virgen extra redujo la CC e incrementó los niveles de HDL-C en pacientes con CAD.

(*Nutr Hosp.* 2015;32:2144-2152)

DOI:10.3305/nh.2015.32.5.9642

Palabras clave: *Enfermedad coronaria arterial. Tratamiento nutricional. Prevención secundaria y aceite de coco virgen extra.*

study included patients of both genders aged 45-85 years on secondary prevention of CAD (myocardial infarction and/or stable angina), with the use of lipid-lowering drugs for longer than six months, seen at an outpatient department of a specialized cardiology hospital during January-September, 2012. It excluded those who had coronary artery bypass grafting and previous cardiovascular event within less than 6 months, those who had chronic renal failure with creatinine levels greater than 1.2 mg/dL, patients using coconut oil, food supplements, and those who suffered from liver diseases.

From the screened population, 136 patients met the eligibility criteria for the three-month run-in phase in order to homogenize or standardize their food intake. From the third month the allocation was performed for two intervention groups: diet group (DG) ( $n = 22$ ), who remained only with diet, and another group that besides diet received extra virgin coconut oil (CODG) ( $n = 92$ ). The study details are better shown in figure 1.

Patients were seen in a monthly basis at the clinical nutrition department of a specialized hospital where they received intensive dietary treatment with periodic phone calls to assess compliance. In addition, all patients were provided with a telephone number to contact to dispel doubts whenever necessary. Socio economic and demographic data, information on past medical history and present illness, drug therapy, and physical exercise<sup>13</sup> were collected. In each visit, 12-hour fasting blood sample was drawn, 24-hour dietary recall was obtained, anthropometric assessment was made and systemic blood pressure (BP) was measured. At the beginning of the run-in period, all patients were given a adequate nutritional status diet and instructed to follow it until the end of the study.

The experimental protocol was approved by the Research Ethics Committee of Instituto Nacional de Cardiología (INC)-RJ under no. 0305/2010, and its National Clinical Trial (NCT) number is 01962844. All the volunteers were informed about the procedures they would undergo during the research, and signed the statement of informed consent (SIC).




Fig. 1.—Flowchart of patients in a clinical trial on the effects of the associated or sole intake of extra virgin coconut oil dietary treatment.

#### Anthropometric measurements, physical activity and blood sampling

The anthropometric measurements body mass (kg) and height (m) were taken using a digital platform scale coupled with a stadiometer (Filizola®)<sup>14</sup>. BMI was calculated by dividing body mass (kg) by height (m) squared<sup>14</sup>, classified according to the World Health Organization (WHO)<sup>15</sup>.

WC was measured at the midpoint between the last rib and the iliac crest<sup>16</sup>. NC was measured with the subject standing with the head positioned in the Frankfort horizontal plane, the upper edge of the tape was placed under the cricoid cartilage and applied perpendicularly around the neck<sup>17</sup>. Blood pressure was measured twice in the right arm by the trained investigator, with a

mercury sphygmomanometer and stethoscope after subjects had rested for a minimum of 10 minutes<sup>18</sup>.

Physical activity was considered when patients trained at least once a week. Physical exercise was assessed as metabolic equivalent of task (MET) expressed in kcal/day<sup>19</sup>. Patients were considered sedentary when they did not perform physical exercise, or when they exercised with caloric expenditure below 3 METs and a frequency of less than two times per week. Patients were advised to keep the level of habitual physical activity.

Blood samples were drawn after 12 hours of overnight fasting. The samples were taken in blood collection vacuum tubes containing heparin. The collection tubes were then centrifuged for 15 min at 4°C and 3.000 rpm.

TG, TC, and HDL-C and LDL-C<sup>20</sup> were analyzed. Serum levels of ApoA-1 and ApoB were measured by

immunoturbidimetric assay<sup>21</sup>. Fasting plasma glucose was measured by the spectrophotometric method using the glucose oxidase/oxidase. The glycated hemoglobin (HbA1c), by turbidimetric immunoassay. All analyses were performed at the clinical laboratory of INC (Rio de Janeiro, Brazil) through the automated method (ARCHITECT ci8200, Architect® Abbott, Abbott Park, IL, USA) using commercial kits (Abbott ARCHITECT c8000®, Abbott Park, IL, USA).

### Diet design and supplementation

The diet was prescribed during the run-in period according to the dietary habits of volunteers and nutritional recommendations for individuals with dyslipidemia<sup>22</sup>. The total energy expenditure was calculated considering the recommendations of the Dietary Reference Intake, 2005<sup>23</sup>, and of the National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATP III) (2002)<sup>24</sup> considering the current BM. At each visit, a 24-hour recall was used to assess patient compliance to the offered nutritional treatment. In order to assess changes in the habitual dietary pattern, baseline 24-hour recalls were compared to those three months after intervention. Data were analyzed using the computer program Food Processor Version 7.2 (Esha Research, Salem, USA, 1998).

The CODG received extra virgin coconut oil in sachets containing 13 mL (30 units per month), totaling 90 sachets per patient. Patients were instructed to consume one sachet per day, alone or added to fruit, without subjecting it to heat.

Coconut oil was donated by COPRA Food Industry, Maceió, AL, Brazil.

The composition of fatty acids of coconut oil was obtained by the Analytical Chemistry Organic La-

boratory of Centro de Pesquisas e Desenvolvimento Leopoldo Américo Miguez de Mello (CENPES)/Rio de Janeiro, RJ, Brazil. Vitamin E and phytosterols contents were determined by the Instituto de Tecnologia de Alimentos/Centro de Ciências e Qualidade de Alimentos, Campinas, São Paulo, SP, Brazil (Table I).

### Statistical analysis

The results were expressed as percentage and mean  $\pm$  standard deviation (SD). The chi-square test ( $\chi^2$  test) was performed to compare categorical variables between groups. Kolmogorov-Smirnov adhesion test was performed.

Paired Student's *t*-test or *Wilcoxon Signed Ranks* was used to assess changes in anthropometric and biochemical variables after the intervention period in each group. While the effect of the intervention groups was evaluated by Student *t* test independent or *Mann-Whitney U test* according to the distribution of variables.

The difference between DG and CODG was evaluated by Student's *t*-test. Through the analysis of variance for repeated measures, DBP was adjusted for BM, and the development of HDL-C and WC in CODG and DG was evaluated. All analyses were performed using SPSS, version 20.0. When  $p < 0.055$ , the finding was considered statistically significant.

### Results

One hundred and thirty-six patients were included in the study. Among them, one hundred and fourteen (85.3%) managed to complete the run-in period. The majority of the participants who abandoned the study

**Table I**  
Nutrient composition of a serving of coconut oil

Coconut oil composition <sup>1</sup>	Composition of fatty acids (%/100g) <sup>2</sup>	Composition of phytosterols and vitamin E <sup>3</sup>	ND < 300 <sup>a</sup>
Energy, kcal/kJ	127/533	C6:0 Caproic	–
Carbs, g	0	C8:0 Caprylic	7,0
Protein, g	0	C10:0 Capric	6,0
Total Fat, g	14	C12:0 Lauric	48,0
Saturated fat, g	13	C14:0 Myristic	19,0
Trans fat, g	0	C16:0 Palmitic	9,0
Monounsaturated fats, g	0.8	C18:1 Stearic	3,0
Polyunsaturated fats, g	0.2	C18:1 PUFA 9 Oleic	8,0
Cholesterol, mg	0		Brassicasterol
Fiber, mg	0		Campesterol
Sodium, mg	0		Stigmasterol
			Beta-sitosterol
			Alpha-tocopherol
			Beta-tocopherol
			Gama-tocopherol
			Delta-tocopherol
			Vitamin E (IU/100 g)

<sup>1</sup>Composition held in 15ml of extra virgin coconut oil = 1 tablespoon.

<sup>2</sup>Source: Laboratory of Analytical Chemistry Organic Cenpes/Rio de Janeiro, RJ, Brazil.

<sup>3</sup>Source: Institute of Food Technology, Science Center and Food Quality, Campinas, São Paulo, SP, Brazil Laboratory.

<sup>a</sup>ND: not detected value; <sup>b</sup>Average and estimated standard deviation; mg/dL: milligram per deciliter; IU: international unit.

did not return after the baseline visit due to scheduling difficulties (Fig. 1).

The main characteristics of the population are shown in table II; there was no significant difference between the studied groups since the beginning of intervention.

The mean age of the studied population was  $62.4 \pm 7.7$  years, with 70% of elderly individuals, and 63.2% of males. There were 100% hypertensive and 94.5% dyslipidemic patients on regular medication to control these diseases.

During the run-in period, there was significant decrease in body mass (BM), body mass index (BMI), neck circumference (NC), waist circumference (WC) and glycemic profile (data not shown).

Table III shows the effect of an extra virgin coconut oil-rich diet on anthropometric data and on the blood pressure (BP) after three months of intervention.

Data showed that the CODG significantly decreased their BM, BMI, NC, WC, with a statistical difference between the groups for WC ( $-2.1 \pm 2.7$ ;  $p < 0.01$ ) (Fig. 2A). We also observed the reduction of diastolic blood pressure (DBP) in the CODG; however, after adjustment for BMI, no significant difference was found (data not shown). There was no significant difference in physical activity between both groups at the beginning and during the phases of the study (data not shown).

CODG presented an increase on serum concentrations of HDL-C (CODG:  $3.1 \pm 7.4$  mg/dL;  $p < 0.01$

vs. DG:  $-1.2 \pm 8.5$  mg/dL;  $p = 0.52$ ) and apoprotein A (apoA) (CODG:  $4.7 \pm 12.7$ ;  $p = 0.01$  vs. DG:  $-3.9 \pm 2.7$ ;  $p = 0.27$ ).

We notice the effect of a coconut-rich diet on the levels of HDL-C in figure 2B. We may also observe a small increase on the concentrations of apoprotein B (apoB) in the CODG, however with no difference on seric concentrations of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC).

The dietary assessment, undertaken through the 24-hour recalls, showed decrease in the total energy expenditure ( $-748.9 \pm 1110.6$  kcal;  $p < 0.01$ ), lipids ( $-4.1 \pm 11.4$ ;  $p < 0.01$ ), saturated fat ( $-2 \pm 5.1\%$ ;  $p < 0.01$ ), cholesterol ( $-70.9 \pm 199.1$  mg/dL;  $p < 0.01$ ) and sodium ( $-814.5 \pm 1583.2$  mg/d;  $p < 0.01$ ), after the run-in period (data not shown). After the run-in period, the CODG presented increased intake of lipids and saturated fatty acids, with reduced carbohydrate intake. There was no modification in the DG group. The statistical analyses showed no difference between the groups.

## Discussion

The results of this study show that the inclusion of 13 mL of extra virgin coconut oil in a diet increases significantly the HDL-C levels and decreases the WC. Previous studies involving the intake of coconut oil have linked it to the reduction of abdominal fat, as the

**Table II**  
Baseline characteristics of the groups CODG and DG<sup>1</sup>

Variables	CODG (n = 2)	DG (n = 22)	p
Age, years	62.5±8.02	63.2±11.5	0.94 <sup>2</sup>
Weight, kg	79.7±15.7	79.59±14.1	0.96 <sup>2</sup>
BMI, kg/m <sup>2</sup>	29.9±5.8	29.7±5.2	0.82 <sup>2</sup>
Inactivity, % (n)	71.1 (66)	81.8 (18)	0.11 <sup>3</sup>
Diabetes mellitus type 2, %(n)	50 (46)	36.4 (8)	0.44 <sup>3</sup>
Hypoglycemic, % (n)	48.9 (45)	40.9 (9)	0.50 <sup>3</sup>
Angina, % (n)	46.7 (43)	40.9 (9)	0.80 <sup>3</sup>
Acute myocardial infarction, % (n)	77.2 (71)	77.3 (17)	0.15 <sup>3</sup>
C-Total, mg/dL	177.5±51.8	176.9±68.6	0.96 <sup>2</sup>
LDL-col, mg/dL	108.3±45.1	114.5±55.5	0.58 <sup>2</sup>
HDL-col, mg/dL	37.5±9.2	37.5±9.3	0.96 <sup>2</sup>
Triglycerides, mg/dL	153.7±71.2	153.0±68.9	0.71 <sup>2</sup>
SBP, mmHg	129.0±19.0	128.1±15.9	0.84 <sup>2</sup>
DBP, mmHg	77.8±11.5	81.3±9.9	0.18 <sup>2</sup>

Abbreviations: SBP: SBP; DBP: diastolic blood pressure; C-total: total cholesterol; HDL-C: high density lipoproteins cholesterol; LDL-C: low density lipoprotein cholesterol; TG-: triglycerides.

<sup>1</sup>Results are expressed as mean ± SD or percentage.

<sup>2</sup>T-Student test between CODG and DG.

<sup>3</sup>Chi-square  $\chi^2$  test between the groups, statistically significant for  $p < 0.05$ .

study by Assunção *et al.*, 2009<sup>25</sup>, after a 30 mL/d supplement of coconut oil in comparison to soy oil, and the study by Liao *et al.*, 2011<sup>26</sup> evaluating the effect of 30 mL/d virgin coconut oil.

According to the literature, extra virgin coconut oil consists mainly of medium-chain triglycerides (MCT), about 60% (Table I). Other studies into the use of MCT show their effect on reducing body weight when compared to long-chain triglycerides (LCT)<sup>27-32</sup>. MCT seem to have a beneficial effect also on abdominal fat<sup>30,31</sup> for which one of the potential mechanisms is the low incorporation of MCT into the adipose tissue.

Another result that draws attention is the reduction of DBP in the group that consumed extra virgin coconut oil. Animal experiments have found the protective effect of coconut oil on blood pressure<sup>33,34,35</sup>; authors attribute this effect to the presence of polyphenols in the oil.

The current study showed the beneficial effects of an extra virgin coconut oil-rich diet on the significant increase of serum levels of HDL-C (5%;  $p = 0.01$ ) with no change in the levels of TC, LDL-C and triglycerides (TG). Feranil *et al.*<sup>36</sup> also found positive association between coconut oil intake and the increase of serum levels of HDL-C. Nevertheless, Assunção *et al.*,

**Table III**  
Effect of dietary intervention with diet and supplementation with extra virgin coconut oil in the anthropometric data and blood pressure<sup>1</sup>

Variables	CODG (n = 92)			DG (n = 22)			
	Baseline	$\Delta T1$	p	Baseline	$\Delta T2$	p	p
Weight, kg	78.1±15.2	-0.6±1.8	<0.01*	78.5±13.9	-0.4±2.2	0.49	0.72
BMI, kg/m <sup>2</sup>	29.3±5.5	-0.2±0.7	<0.01*	29.3±5.1	-0.1±0.8	0.51	0.56
WC, cm	100.1±11.8	-2.1±2.7	<0.01*	100.2±10.7	-0.2±2.6	0.37	<0.01**
NC, cm	38.0±3.8	-0.4±0.9	<0.01*	38.4±3.8	-0.2±0.8	2.34	0.31
SBP, mmHg	129.0±19	-3.3±18.2	0.06	128.1±15.9	0.9±13.7	0.76	0.32
DBP, mmHg	77.8±11.5	-3.5±13.8	<0.01*	81.3±9.9	-4.3±10	0.05	0.60

Abbreviations: BMI: body mass index; NC: neck perimeter; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure.

<sup>1</sup>Results in mean ± SD.

$\Delta T1$  = (3 months-baseline);  $\Delta T2$  = (3 months-baseline).

\*Statistically significant between 3 months ( $p < 0.05$ ).

\*\*Statistically comparing the mean DG and CODG groups ( $p < 0.05$ ).

**Table IV**  
Effect of dietary intervention with diet and supplementation with extra virgin coconut oil in lipid profile<sup>1</sup>

Variables	CODG (n = 92)			DG (n = 22)			
	Baseline	$\Delta T1$	p	Baseline	$\Delta T2$	p	p
TC, mg/dL	177.4±51.8	5.9±35.4	0.11	176.9±68.6	11.2±31.6	0.11	0.61
HDL-C, mg/dL	37.5±9.2	3.1±7.4	<0.01*	37.6±9.3	-1.2±8.5	0.52	<0.01**
LDL-C, mg/dL	108.3±45.2	4.0±31.2	0.13	114.5±55.6	2.6±32.7	0.70	0.77
TG, mg/dL	153.8±71.2	-2.0±70.5	0.78	153.0±69.0	23.3±72.4	0.14	0.13
ApoA, mg/dL	137.2±18.9	4.7±12.7	0.01*	141.8±18.9	-3.9±2.7	0.20	0.27
ApoB, mg/dL	94.9±23.4	6.4±17.6	0.01*	95.0±21.1	7.4±18.1	0.07	0.66
Glucose, mg/dL	118.0±34.1	1.4±23.6	0.57	116.0±42.7	-4.2±25.2	0.44	0.32
HgA1, mg/dL	6.2±1.1	0.1±0.6	0.05	6.1±0.7	0.1±1.0	0.62	0.14
UA, mg/dL	5.8±1.5	0.3±1.3	0.05	6.2±1.5	-0.0±1.0	0.94	0.24

Abbreviations: TC: total cholesterol; HDL-C: high density lipoproteins cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglycerides; ApoA: apoprotein A; ApoB: Apoprotein B; HbA1C: glycated hemoglobin; UA: uric acid.

<sup>1</sup>Results in mean ± SD.

$\Delta T1$  = (3 months-baseline);  $\Delta T2$  = (3 months-baseline).

\*Within 3 months statistically significant ( $p < 0.05$ ).

\*\*Statistically comparing the mean DG and CODG groups ( $p < 0.05$ ).

**Table V**  
Dietary characteristics during the intervention<sup>1</sup>

Variables	CODG (n = 92)			DG (n = 22)			
	Baseline	$\Delta T1$	p	Baseline	$\Delta T2$	p	p
Energy, kcal	1508.3±669.6	76.5±707.2	0.31	1580.3±565.5	-0.5±858.2	0.98	0.69
PTN, %VET	24.1±7.1	-1.8±9.8	0.09	25.3±8.5	-1.7±12.5	0.58	0.97
CHO, %VET	55.5±9.6	-3.0±11.2	<b>0.01*</b>	55.1±11.2	-2.9±16.7	0.49	0.98
LIP, %VET	20.1±8.5	4.5±9.6	<b>&lt;0.01*</b>	20.1±9.2	4.9±18.2	0.29	0.89
SFA, %	6.5±3.6	5.9±4.8	<b>&lt;0.01*</b>	6.4±2.6	3.7±10.3	0.16	0.17
MFA, %	6.2±4.1	0.2±5.4	0.67	6.9±4.4	0.5±6.8	0.78	0.87
PFA, %	3.4±2.6	-0.6±3.3	0.12	3.3±2.8	-0.2±3.8	0.85	0.89
Cholesterol, mg/d	179.8±122.6	-10.9±170.7	0.54	212.8±137.0	54.9±288.6	0.44	0.20
Sodium, mg/d	1311.2±768.7	-57.7±894.7	0.54	1251.4±680.8	368.1±1092.0	0.18	0.06
Fiber, g/d	26.9±16.6	-0.3±18.7	0.86	25.7±11.0	-6.8±10.3	<b>0.01*</b>	0.19

Abbreviation: PTN: protein; CHO: carbohydrate; LIP: lipids; SFA: saturated fatty acids; MFA: monounsaturated fatty acids; PFA: polyunsaturated fatty acids.

<sup>1</sup>Resultados expressos em média ± SD.

$\Delta T1$  = (3 months-baseline);  $\Delta T2$  = (3 months-baseline).

\*Within 3 months statistically significant (p < 0.05).




Fig. 2.—Evolution of WC (A) and HDL-C (B) between the groups (DG x CODG) during the three-month intervention. \*Test of analysis of variance for repeated measures, p < 0.05.

2009<sup>25</sup>, by comparing refined coconut oil and refined soy oil, did not find any benefit in the lipid profile, and Liao *et al.* 2011<sup>26</sup> did not find any effect either. Two other studies with isolated MCT also found no important change in the lipid profile<sup>30,31</sup>.

Experimental studies in which animals were fed diets supplemented with virgin coconut oil showed increased levels of HDL-C and decreased levels of LDL-C, TG and TC<sup>37</sup>. Authors credited the results to the action of polyphenols and vitamin E, present in the virgin coconut oil. Besides, saturated fat is known to have a role in the improvement of HDL-C

levels by increasing the activity of lecithin cholesterol acetyltransferase (LCAT)<sup>38</sup>. The elevation of HDL-C levels, with no change in LDL-C levels, in our population of chronic CAD patients was highly significant, for evidence point that normal concentrations of HDL-C are associated with minor risk of non-lethal infarct<sup>39</sup> and low concentrations of HDL-C are strong predictors of infarct<sup>40</sup>. And further, that the lower the LDL-C the lower the cardiovascular morbidity and mortality<sup>41</sup>.

Dietary interventions that contribute to the increase of HDL concentrations are rare; therefore our findings

were highly significant and unprecedented in this group of patients with chronic coronary disease. The intake of this kind of fat meets strong opposition from people in general, although studies have not proved the association between the intake of saturated fat and cardiovascular disease or CAD<sup>42</sup>. Also, considering a specific population that regularly used this coconut oil, there was no positive association with the onset of cardiovascular disease<sup>10</sup>.

Our study presents some limitations: small sample size in the diet group, absence of randomization when allocating patients to nutritional intervention. However, it is noteworthy that CODG and DG were comparable in relation to anthropometric and biochemical data.

## Conclusion

Nonpharmacological interventions are essential for risk factor control in secondary prevention among patients with coronary disease. Our study showed that a diet rich in extra virgin coconut oil seems to favor the reduction of WC and the increase of HDL-C concentrations, aiding with secondary prevention for CAD patients.

## Acknowledgment

This study was funded by Institute of National Cardiology. The authors declare no conflicts of interest.

## Authors' contributions

DAC, GMMO, ABM, RRL and GR were responsible for the study conception and design, and the drafting of the manuscript; DAC, GMMO, ABM, RRL and GR participated in the analysis and interpretation of data; GMMO, ABM and GR critically revised the article for intellectual content; RRL developed the statistics; all authors are accountable for the final approval of the manuscript. None of the authors had a conflict of interest.

## References

1. Smith SC, Benjamin C, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, James HS, Stein and Kathryn A, Taubert Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, John BA, Stein and Kathryn A, Taubert S and K. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: Update A Guideline From the American Heart Association and American College of Cardiology Foundation. *Circulation* 2011; 124(22): 2458-73.
2. Ford E S, M.D, Umed A, Ajani, M.B, Janet B. Croft, Critchley JA, Phil D, Darwin R. Labarthe, Thomas E. Kottke, M.D., Wayne H. Giles, M.D and Simon Capewell, M.D. Explaining

the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med* 2007; 356(23): 2388-98.

3. Garaulet M, Pérez de Heredia F. Behavioural therapy in the treatment of obesity (I): new directions for clinical practice. *Nutr Hosp* 2009; 24 (6): 629-39.
4. Tang L, Patao C, Chuang J, and Wong ND, Cardiovascular Risk Factor Control and Compliance to Recommended Lifestyle and Medical Therapies in Persons With Coronary Heart Disease (from the National Health and Nutrition Examination Survey 2007e2010). *Am J Cardiol* 2011; 112 (8): 1126-32.
5. Huang J, Frohlich J, Ignasewski AP. The impact of dietary changes and dietary supplements on lipid profile. *Can J Cardiol* 2011; 27: 488-505.
6. Jenkins DJ, Srichaikul K, Mirrahimi A, Chiavaroli L, Kendall CW. Functional foods to increase the efficacy of diet in lowering serum cholesterol. *Can J Cardiol*. 2011; 27(4): 397-400.
7. Li DF, Thaler RC, Nelssen JL, Harmon DL, Allee GL, Weeden TL. Effect of fat sources and combinations on beginning pig performance, nutrient digestibility and intestinal morphology. *J Anim Sci* 1990; 68(11): 3694-704.
8. Nevin KG, Rajamohan T. Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. *Clin Biochem* 2008; 37 (9): 830-5.
9. Lipoeto NI, Agus Z, Oenzil F, Wahlqvist M, Wattanapenpaiboon N. Dietary intake and the risk of coronary heart disease among the coconut-consuming Minangkabau in West Sumatra, Indonesia. *Asia Pac J Clin Nutr* 2004; 13(4): 377-84.
10. Prior I, Davidson F, Salmond C, Czochanska Z. Cholesterol, coconuts and diet on Polynesian atolls: a natural experiment: The Pukapula and Tokelau Island Studies. *Am J Clin Nutr* 1981; 34(8): 1552-61.
11. Lindeberg S, Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island: a clinical study in Kitava. *J Intern Med* 1993; 233: 269-275.
12. Kumar PD. The role of coconut and coconut oil in coronary heart disease in Kerala, south India. *Tropical Doctor* 1997; 27: 215-217.
13. Gomes VB, Siqueira KS, Sichieri R. Physical activity among a random sample of the Rio de Janeiro. *Cad Saude Publica* 2001; 17(4): 969-76.
14. Gibson RS. Principles of nutritional assessment. New York: Oxford, 1990. P.691.
15. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva, Switzerland: *World Health Organ Tech Rep Ser*. 2000; 894: i-xii, 1-253.
16. Després JP. Health consequences of visceral obesity. *Annals of medicine* 2001; 33(8): 534-41.
17. Ben-Noun L, Sohar E, Laor A. Neck circumference as a simple screening measure for identifying overweight and obese patients. *Obes Res* 2001; 9(8): 470-7.
18. Alessi A, Brandão AA, Pierin Â, Feitosa AM, Machado CA, Forjaz CLdM et al. IV Diretriz para uso da Monitorização Ambulatorial da Pressão Arterial - II Diretriz para uso da Monitorização Residencial da Pressão Arterial IV MAPA / II MRPA. *Arquivos Brasileiros de Cardiologia*. 2005; 85: 1-18.
19. Ainsworth BE, Haskell WL, Herrmann SD, Nathanael M, David B, Catrine T-L, Jennifer G, Jesse V, Melicia W-G, Arthur S LEON. Compendium of Physical Activities: a second update of codes and MET values. *Med Sci Sports Exerc* 2011; 43(8): 1575-81.
20. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
21. Ledue TB, Collins MF, Ritchie RF. Development of immunoturbidimetric assays for fourteen human serum proteins on the Hitachi 912. *Clin Chem Lab Med* 2002; 40(5): 520-8.
22. Sposito AC, Caramelli B, Fonseca FAH, Bertolami MC, Afíune Neto A, Souza AD et al. IV Diretriz Brasileira sobre Dislipidemias e Prevenção da Aterosclerose: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. *Arquivos Brasileiros de Cardiologia* 2007; 88: 2-19.

23. Washington, DC. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). In: Council NR, editor.: The National Academies Press; 2005. p. 1. Print.
24. Grundy SM, Becker D, Clark LT, Luther T, Richard S, Cooper, Margo A, Denke, M.D., Wm. James Howard, Hunninghake D B, Roger D I., Luepker R V, McBride P, McKenney JM, Richard C. PP, Stone NJ, Van Horn L. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19): 2486-97.
25. Assunção ML, Ferreira HS, dos Santos AF, Cabral CR Jr, Florêncio TM. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity. *Lipids* 2009; 44(7): 593-601.
26. Liau KM, Lee YY, Chen CK, Rasool AH. An open-label pilot study to assess the efficacy and safety of virgin coconut oil in reducing visceral adiposity. *ISRN Pharmacol* 2011; 949686.
27. Hainer V, Kunesová M, Stich V, Zák A, Parizková J. The role of oils containing triacylglycerols and medium-chain fatty acids in the dietary treatment of obesity. The effect on resting energy expenditure and serum lipids. *Cas Lek Cesk* 1994; 13; 133(12): 373-5.
28. Tsuji H, Kasai M, Takeuchi H, Nakamura M, Okazaki M, Kondo K. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women. *J Nutr* 2001; 131(11): 2853-9.
29. Krotkiewski M. Value of VLCD supplementation with medium chain triglycerides. *Int J Obes Relat Metab Disord* 2001; 25(9): 1393-400.
30. Nosaka N, Maki H, Suzuki Y, Haruna H, Ohara A, Kasai M, Tsuji H, Aoyama T, Okazaki M, Igarashi O, Kondo K. Effects of margarine containing medium-chain triacylglycerols on body fat reduction in humans. *J Atheroscler Thromb* 2003; 10(5): 290-8.
31. St-Onge MP, Ross R, Parsons WD, Jones PJ. Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. *Obes Res* 2003; 11(3): 395-402.
32. Han JR, Deng B, Sun J, Chen CG, Corkey BE, Kirkland JL, Ma J, Guo W. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. *Metabolism* 2007; 56(7): 985-91.
33. Nurul-Iman BS, Kamisah Y, Jaarin K, Qodriyah HM. Virgin coconut oil prevents blood pressure elevation and improves endothelial functions in rats fed with repeated L y heated palm oil. *Evid Based Complement Alternat Med* 2013; 2013: 629329.
34. Marina A. M., Che Man Y. B., Nazimah S. A. H, Amin I. Antioxidant capacity and phenolic acids of virgin coconut oil. *International Journal of Food Sciences and Nutrition* 2009; 60(2): 114-123.
35. Nevin K. G, Rajamohan T. Virgin coconut oil supplemented diet increases the antioxidant status in rats. *Food Chemistry* 2006; 99(2): 260-266.
36. Feranil A B, Duazo PL, Kuzawa C W, Adair LS. Coconut oil predicts a beneficial lipid profile in pre-menopausal women in the Philippines. *Asia Pac J Clin Nutr* 2011; 20(2): 190-195.
37. Nevin- K.G & Rajamohan T. Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. *Clinical Biochemistry* 2004; 37(9): 830-5.
38. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A metaanalysis of 27 trials. *Arterioscler Thromb* 1992; 12(8): 911-9.
39. Meisinger C, Loewell H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women : results from the Monica / Kora Augsburg cohort study. *Eur Heart J* 2004; 26(3): 271-8.
40. Bolibar I, Van Eckardstein A, Assman G, Thompson E. Short-term prognostic value of lipid measurement in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. *Thromb Haemost* 2000; 84(6): 955-60.
41. Emilia Arrebola Vivas, Bricia López Plaza, Thabata Koester Weber, Laura Bermejo López, Samara Palma Milla, Arturo Lisbona Catalán y Carmen Gómez-Candela. Variables predictoras de baja adherencia a un programa de modificación de estilos de vida para el tratamiento del exceso de peso en atención primaria. *Nutr Hosp* 2013; 28(5): 1530-1535.
42. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr* 2010; 91: 535-46.